Critical review reveals menin inhibitors show promise in improving outcomes for patients with NPM1m and KMT2Ar acute leukemia, indicating a shift in treatment strategies.
Key Points
Menin inhibitors offer a unified therapeutic strategy for distinct acute leukemia subgroups like NPM1m and KMT2Ar.
Acute myeloid leukemia with NPM1 mutations has a 30% occurrence rate; KMT2A rearrangements are 5-10% of cases.
The MEIS1-HOXA axis activation is linked to poor prognosis in relapsed acute leukemia settings.
Six menin inhibitors, including revumenib and ziftomenib, are in clinical evaluation, targeting high-risk populations.